O	0	10	Antibodies	Antibody	NNS	B-NP
O	11	13	to	to	TO	B-PP
O	14	17	PAI	PAI	NN	B-NP
O	17	18	-	-	HYPH	B-NP
O	18	19	1	1	CD	I-NP
O	20	25	alter	alter	VBP	B-VP
O	26	29	the	the	DT	B-NP
O	30	38	invasive	invasive	JJ	I-NP
O	39	42	and	and	CC	I-NP
O	43	52	migratory	migratory	JJ	I-NP
O	53	63	properties	property	NNS	I-NP
O	64	66	of	of	IN	B-PP
O	67	72	human	human	JJ	B-NP
B-Cell	73	79	tumour	tumour	NN	I-NP
I-Cell	80	85	cells	cell	NNS	I-NP
O	86	88	in	in	FW	B-ADVP
O	89	94	vitro	vitro	FW	I-ADVP
O	94	95	.	.	.	O

O	97	103	Recent	Recent	JJ	B-NP
O	104	111	reports	report	NNS	I-NP
O	112	119	suggest	suggest	VBP	B-VP
O	120	124	that	that	IN	B-SBAR
O	125	133	elevated	elevated	JJ	B-NP
O	134	140	levels	level	NNS	I-NP
O	141	143	of	of	IN	B-PP
O	144	155	plasminogen	plasminogen	NN	B-NP
O	156	165	activator	activator	NN	I-NP
O	166	175	inhibitor	inhibitor	NN	I-NP
O	175	176	-	-	HYPH	B-NP
O	176	177	1	1	CD	I-NP
O	178	179	(	(	(	O
O	179	182	PAI	PAI	NN	B-NP
O	182	183	-	-	HYPH	B-NP
O	183	184	1	1	CD	I-NP
O	184	185	)	)	)	O
O	186	189	may	may	MD	B-VP
O	190	200	contribute	contribute	VB	I-VP
O	201	203	to	to	TO	B-PP
B-Cancer	204	210	tumour	tumour	NN	B-NP
O	211	222	progression	progression	NN	I-NP
O	222	223	.	.	.	O

O	224	227	The	The	DT	B-NP
O	228	235	studies	study	NNS	I-NP
O	236	244	reported	report	VBN	B-VP
O	245	249	here	here	RB	B-ADVP
O	250	254	were	be	VBD	B-VP
O	255	263	designed	design	VBN	I-VP
O	264	266	to	to	TO	I-VP
O	267	271	help	help	VB	I-VP
O	272	281	elucidate	elucidate	VB	I-VP
O	282	285	PAI	PAI	NN	B-NP
O	285	286	-	-	HYPH	B-NP
O	286	287	1	1	CD	I-NP
O	287	288	'	'	SYM	I-NP
O	288	289	s	s	NN	I-NP
O	290	302	contribution	contribution	NN	I-NP
O	303	305	to	to	TO	B-PP
O	306	309	the	the	DT	B-NP
O	310	318	invasive	invasive	JJ	I-NP
O	319	322	and	and	CC	I-NP
O	323	332	migratory	migratory	JJ	I-NP
O	333	342	phenotype	phenotype	NN	I-NP
O	342	343	.	.	.	O

O	344	354	Antibodies	Antibody	NNS	B-NP
O	355	357	to	to	TO	B-PP
O	358	360	PA	PA	NN	B-NP
O	360	361	-	-	HYPH	O
O	361	362	1	1	CD	B-NP
O	363	367	dose	dose	NN	I-NP
O	367	368	-	-	HYPH	B-VP
O	368	379	dependently	dependently	RB	B-ADVP
O	379	380	,	,	,	O
O	381	384	and	and	CC	O
O	385	398	significantly	significantly	RB	B-ADVP
O	398	399	,	,	,	O
O	400	409	inhibited	inhibit	VBD	B-VP
O	410	413	the	the	DT	B-NP
O	414	422	invasive	invasive	JJ	I-NP
O	423	426	and	and	CC	I-NP
O	427	436	migratory	migratory	JJ	I-NP
O	437	446	potential	potential	NN	I-NP
O	447	449	of	of	IN	B-PP
O	450	455	human	human	JJ	B-NP
B-Cell	456	462	HT1080	HT1080	NN	I-NP
I-Cell	463	475	fibrosarcoma	fibrosarcoma	NN	I-NP
I-Cell	476	481	cells	cell	NNS	I-NP
O	481	482	,	,	,	O
O	483	485	as	as	IN	B-SBAR
O	486	489	did	do	VBD	O
O	490	492	an	an	DT	B-NP
O	493	501	antibody	antibody	NN	I-NP
O	502	504	to	to	TO	B-PP
O	505	508	uPA	uPA	NN	B-NP
O	509	512	and	and	CC	O
O	513	516	the	the	DT	B-NP
O	517	524	plasmin	plasmin	NN	I-NP
O	525	534	inhibitor	inhibitor	NN	I-NP
O	535	544	aprotinin	aprotinin	NN	I-NP
O	544	545	.	.	.	O

O	546	554	Invasion	Invasion	NN	B-NP
O	555	557	of	of	IN	B-PP
O	558	561	the	the	DT	B-NP
O	562	567	human	human	JJ	I-NP
B-Cell	568	576	melanoma	melanoma	NN	I-NP
I-Cell	577	581	cell	cell	NN	I-NP
I-Cell	582	586	line	line	NN	I-NP
O	586	587	,	,	,	O
B-Cell	588	591	BLM	BLM	NN	B-NP
O	591	592	,	,	,	O
O	593	596	was	be	VBD	B-VP
O	597	601	also	also	RB	I-VP
O	602	612	attenuated	attenuate	VBN	I-VP
O	613	615	by	by	IN	B-PP
O	616	619	the	the	DT	B-NP
O	620	624	anti	anti	AFX	I-NP
O	624	625	-	-	HYPH	I-NP
O	625	628	PAI	PAI	NN	I-NP
O	628	629	-	-	HYPH	B-NP
O	629	630	1	1	CD	I-NP
O	631	641	monoclonal	monoclonal	JJ	I-NP
O	642	650	antibody	antibody	NN	I-NP
O	651	654	MAI	MAI	NN	I-NP
O	654	655	-	-	HYPH	O
O	655	657	12	12	CD	B-NP
O	657	658	.	.	.	O

O	659	662	The	The	DT	B-NP
O	663	666	non	non	AFX	I-NP
O	666	667	-	-	HYPH	I-NP
O	667	675	invasive	invasive	JJ	I-NP
O	676	681	human	human	JJ	I-NP
B-Cell	682	690	melanoma	melanoma	NN	I-NP
I-Cell	691	695	cell	cell	NN	I-NP
I-Cell	696	700	line	line	NN	I-NP
O	700	701	,	,	,	O
B-Cell	702	705	IF6	IF6	NN	B-NP
O	705	706	,	,	,	O
O	707	712	which	which	WDT	B-NP
O	713	717	does	do	VBZ	B-VP
O	718	721	not	not	RB	I-VP
O	722	729	express	express	VB	I-VP
O	730	733	uPA	uPA	NN	B-NP
O	733	734	,	,	,	O
O	735	743	provided	provide	VBN	B-PP
O	744	751	further	further	JJ	B-NP
O	752	764	confirmation	confirmation	NN	I-NP
O	765	767	of	of	IN	B-PP
O	768	771	PAI	PAI	NN	B-NP
O	771	772	-	-	HYPH	B-NP
O	772	773	1	1	CD	I-NP
O	774	777	and	and	CC	I-NP
O	778	781	uPA	uPA	NN	I-NP
O	781	782	'	'	''	O
O	782	783	s	s	VBZ	B-VP
O	784	788	role	role	NN	B-NP
O	789	791	as	as	IN	B-SBAR
O	791	792	,	,	,	O
O	793	797	upon	upon	IN	B-PP
O	798	810	transfection	transfection	NN	B-NP
O	811	815	with	with	IN	B-PP
O	816	819	uPA	uPA	NN	B-NP
O	819	820	,	,	,	O
O	821	825	this	this	DT	B-NP
B-Cell	826	830	cell	cell	NN	I-NP
I-Cell	831	835	line	line	NN	I-NP
O	836	844	attained	attain	VBD	B-VP
O	845	847	an	an	DT	B-NP
O	848	856	invasive	invasive	JJ	I-NP
O	857	866	phenotype	phenotype	NN	I-NP
O	866	867	,	,	,	O
O	868	873	which	which	WDT	B-NP
O	874	877	was	be	VBD	B-VP
O	878	883	again	again	RB	I-VP
O	884	894	attenuated	attenuate	VBN	I-VP
O	895	897	by	by	IN	B-PP
O	898	901	MAI	MAI	NN	B-NP
O	901	902	-	-	HYPH	B-NP
O	902	904	12	12	CD	I-NP
O	904	905	.	.	.	O

O	906	914	Although	Although	IN	B-SBAR
O	915	925	antibodies	antibody	NNS	B-NP
O	926	928	to	to	TO	B-PP
O	929	932	PAI	PAI	NN	B-NP
O	932	933	-	-	HYPH	B-NP
O	933	934	1	1	CD	I-NP
O	935	938	did	do	VBD	B-VP
O	939	942	not	not	RB	I-VP
O	943	949	affect	affect	VB	I-VP
O	950	953	the	the	DT	B-NP
O	954	962	adhesion	adhesion	NN	I-NP
O	963	965	of	of	IN	B-PP
B-Cell	966	972	HT1080	HT1080	NN	B-NP
I-Cell	973	978	cells	cell	NNS	I-NP
O	979	981	to	to	TO	B-PP
O	982	993	vitronectin	vitronectin	NN	B-NP
O	993	994	,	,	,	O
O	995	998	the	the	DT	B-NP
O	999	1007	antibody	antibody	NN	I-NP
O	1008	1010	to	to	TO	B-PP
O	1011	1014	uPA	uPA	NN	B-NP
O	1015	1022	reduced	reduce	VBD	B-VP
O	1023	1028	their	their	PRP$	B-NP
O	1029	1039	attachment	attachment	NN	I-NP
O	1039	1040	.	.	.	O

O	1041	1049	Addition	Addition	NN	B-NP
O	1050	1052	of	of	IN	B-PP
O	1053	1062	exogenous	exogenous	JJ	B-NP
O	1063	1066	PAI	PAI	NN	I-NP
O	1066	1067	-	-	HYPH	B-NP
O	1067	1068	1	1	CD	I-NP
O	1068	1069	,	,	,	O
O	1070	1077	however	however	RB	B-ADVP
O	1077	1078	,	,	,	O
O	1079	1088	prevented	prevent	VBD	B-VP
B-Cell	1089	1095	HT1080	HT1080	NN	B-NP
I-Cell	1096	1100	cell	cell	NN	I-NP
O	1101	1109	adhesion	adhesion	NN	I-NP
O	1110	1111	(	(	(	O
O	1111	1115	IC50	IC50	NN	B-NP
O	1116	1119	180	180	CD	I-NP
O	1120	1122	nM	nM	NN	I-NP
O	1122	1123	)	)	)	O
O	1124	1127	and	and	CC	O
O	1128	1136	promoted	promote	VBD	B-VP
B-Cell	1137	1141	cell	cell	NN	B-NP
O	1142	1152	detachment	detachment	NN	I-NP
O	1153	1157	from	from	IN	B-PP
O	1158	1169	vitronectin	vitronectin	NN	B-NP
O	1169	1170	.	.	.	O

O	1171	1182	Furthermore	Furthermore	RB	B-ADVP
B-Cell	1183	1191	melanoma	melanoma	NN	B-NP
I-Cell	1192	1197	cells	cell	NNS	I-NP
O	1198	1209	transfected	transfecte	VBN	B-VP
O	1210	1214	with	with	IN	B-PP
O	1215	1216	a	a	DT	B-NP
O	1217	1220	uPA	uPA	NN	I-NP
O	1221	1228	variant	variant	NN	I-NP
O	1228	1229	,	,	,	O
O	1230	1235	which	which	WDT	B-NP
O	1236	1239	had	have	VBD	B-VP
O	1240	1242	an	an	DT	B-NP
O	1243	1251	impaired	impaired	JJ	I-NP
O	1252	1263	interaction	interaction	NN	I-NP
O	1264	1268	with	with	IN	B-PP
O	1269	1272	PAI	PAI	NN	B-NP
O	1272	1273	-	-	HYPH	B-NP
O	1273	1274	1	1	CD	I-NP
O	1274	1275	,	,	,	O
O	1276	1280	were	be	VBD	B-VP
O	1281	1284	not	not	RB	O
O	1285	1293	invasive	invasive	JJ	B-ADJP
O	1294	1297	and	and	CC	O
O	1298	1301	had	have	VBD	B-VP
O	1302	1310	impaired	impair	VBN	I-VP
O	1311	1318	binding	binding	NN	B-NP
O	1319	1321	to	to	TO	B-PP
O	1322	1333	vitronectin	vitronectin	NN	B-NP
O	1333	1334	.	.	.	O

O	1335	1340	These	These	DT	B-NP
O	1341	1345	data	datum	NNS	I-NP
O	1346	1355	highlight	highlight	VBP	B-VP
O	1356	1359	the	the	DT	B-NP
O	1360	1370	importance	importance	NN	I-NP
O	1371	1373	of	of	IN	B-PP
O	1374	1375	a	a	DT	B-NP
O	1376	1384	balanced	balanced	JJ	I-NP
O	1385	1396	proteolysis	proteolysis	NN	I-NP
O	1397	1400	and	and	CC	O
O	1401	1408	suggest	suggest	VBP	B-VP
O	1409	1411	an	an	DT	B-NP
O	1412	1422	additional	additional	JJ	I-NP
O	1423	1427	role	role	NN	I-NP
O	1428	1431	for	for	IN	B-PP
O	1432	1435	PAI	PAI	NN	B-NP
O	1435	1436	-	-	HYPH	B-NP
O	1436	1437	1	1	CD	I-NP
O	1438	1446	distinct	distinct	JJ	B-ADJP
O	1447	1451	from	from	IN	B-PP
O	1452	1455	its	its	PRP$	B-NP
O	1456	1460	role	role	NN	I-NP
O	1461	1463	in	in	IN	B-PP
O	1464	1475	proteolysis	proteolysis	NN	B-NP
O	1475	1476	.	.	.	O

O	1477	1482	These	These	DT	B-NP
O	1483	1487	data	datum	NNS	I-NP
O	1488	1492	also	also	RB	B-ADVP
O	1493	1500	suggest	suggest	VBP	B-VP
O	1501	1505	that	that	IN	B-SBAR
O	1506	1509	uPA	uPA	NN	B-NP
O	1510	1513	and	and	CC	I-NP
O	1514	1517	PAI	PAI	NN	I-NP
O	1517	1518	-	-	HYPH	B-NP
O	1518	1519	1	1	CD	I-NP
O	1520	1523	may	may	MD	B-VP
O	1524	1526	co	co	AFX	B-NP
O	1526	1527	-	-	HYPH	I-NP
O	1527	1534	operate	operate	NN	B-NP
O	1535	1537	in	in	IN	B-PP
O	1538	1541	the	the	DT	B-NP
O	1542	1551	migratory	migratory	JJ	I-NP
O	1552	1559	process	process	NN	I-NP
O	1560	1562	by	by	IN	B-PP
O	1563	1575	respectively	respectively	RB	B-VP
O	1576	1588	facilitating	facilitate	VBG	I-VP
O	1589	1592	the	the	DT	B-NP
O	1593	1603	attachment	attachment	NN	I-NP
O	1604	1606	to	to	TO	B-PP
O	1606	1607	,	,	,	O
O	1608	1611	and	and	CC	O
O	1612	1622	subsequent	subsequent	JJ	B-NP
O	1623	1633	detachment	detachment	NN	I-NP
O	1634	1638	from	from	IN	B-PP
O	1638	1639	,	,	,	O
O	1640	1651	vitronectin	vitronectin	NN	B-NP
O	1652	1654	in	in	IN	B-PP
O	1655	1658	the	the	DT	B-NP
B-Cellular_component	1659	1672	extracellular	extracellular	JJ	I-NP
I-Cellular_component	1673	1679	matrix	matrix	NN	I-NP
O	1679	1680	.	.	.	O

O	1681	1686	These	These	DT	B-NP
O	1687	1694	results	result	NNS	I-NP
O	1695	1702	support	support	VBP	B-VP
O	1703	1706	the	the	DT	B-NP
O	1707	1715	clinical	clinical	JJ	I-NP
O	1716	1724	findings	finding	NNS	I-NP
O	1725	1728	and	and	CC	O
O	1729	1737	indicate	indicate	VBP	B-VP
O	1738	1742	that	that	IN	B-SBAR
O	1743	1753	modulation	modulation	NN	B-NP
O	1754	1756	of	of	IN	B-PP
O	1757	1760	PAI	PAI	NN	B-NP
O	1760	1761	-	-	HYPH	B-NP
O	1761	1762	1	1	CD	I-NP
O	1763	1771	activity	activity	NN	I-NP
O	1772	1775	may	may	MD	B-VP
O	1776	1778	be	be	VB	I-VP
O	1779	1781	of	of	IN	B-PP
O	1782	1793	therapeutic	therapeutic	JJ	B-NP
O	1794	1801	benefit	benefit	NN	I-NP
O	1802	1805	for	for	IN	B-PP
O	1806	1809	the	the	DT	B-NP
O	1810	1819	treatment	treatment	NN	I-NP
O	1820	1822	of	of	IN	B-PP
B-Cancer	1823	1829	cancer	cancer	NN	B-NP
O	1829	1830	.	.	.	O

